Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience

Clin Exp Hypertens. 2006 Apr-May;28(3-4):397-404. doi: 10.1080/10641960600549876.


The use of intravenous recombinant tissue plasminogen activator (rt-PA) administered within 3 hrs from symptom onset is beneficial in selected patients independent of age; although oldest patients (> or = 80 years) are excluded a priori. We report an experience relative to rt-PA treatment in the oldest patients including outcome at 3 months. Data were from the hospital-based Perugia Stroke Registry. Seventy-two consecutive acute stroke patients, fulfilling NINDS and EUSI-criteria were treated with rt-PA of these 23 patients (30.5%) were > or = 80 years. The median and mean age were, respectively, 72.5 and 71.1 +/- 12.7 years (range 35-94). The proportion of favorable outcome at 3-months did not differ between groups (55% elderly versus 51.1% of younger patients). Proportions of unfavorable outcome and death from baseline were similar in both groups of patients. Age did not influence prognosis in patients treated with rt-PA. The oldest stroke patients should not be excluded from rt-PA treatment on the basis of age per se.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Intensive Care Units*
  • Italy
  • Male
  • Middle Aged
  • Recombinant Proteins / therapeutic use*
  • Retrospective Studies
  • Stroke / drug therapy*
  • Stroke / epidemiology
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome
  • Urban Population*


  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator